Kate Moss’ sister issued a warning to anyone taking Ozempic after the English model was rushed to the hospital.
Lottie, 26, admitted she took Ozempic for two weeks “a few months ago.” At the time, she had not been feeling “happy” about her weight.
“I had a friend, and she could get it for me,” Lottie explained during an episode of her “Dream On with Lottie Moss” podcast. “It was kind of below board… It was from a doctor, but it wasn’t like you go into a doctor’s office, and he prescribes it for you, he takes your blood pressure and takes tests, which is what you need when you go on something like Ozempic.”
BROOKE BURKE WARNS OZEMPIC CAN BE ‘DANGEROUS,’ SHARES BENEFITS OF BIOHACKING: THERE’S NO ‘QUICK FIX’
Lottie Moss warned her followers about taking Ozempic after she was rushed to the hospital. (Getty Images)
The British model acknowledged that Ozempic was “not really meant for weight loss of people that aren’t of a very large size.”
Ozempic, also known as semaglutide, was originally created for patients with Type 2 diabetes but has been widely used for weight loss.
“When I was taking it, the amount that I was taking was actually meant for people who are [220 pounds] and over, and I’m in the [110] range,” Lottie said. “So, it’s these small things that I wish I’d known before taking it.”
LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS
APP USERS CLICK HERE TO VIEW THE INSTAGRAM POST
Lottie then encouraged listeners not to take Ozempic.
“When I tell you it was the worst decision I ever made, so if this is a warning to anyone: Please, if you’re thinking of taking it, do not take it, it’s so not worth it,” Lottie said. “I would rather die any day than take that again. It made me feel so nauseous.”
After throwing up constantly, Lottie dropped nearly 20 pounds.
“I think I started at about [132 pounds], and I went down to [125 pounds] with the first dose, then I went down to like [119 pounds]. It was crazy. I think my lowest was [116 pounds]. In terms of a few weeks, that’s not a healthy weight loss, and that’s not a healthy drop.”
Lottie Moss said she suffered a seizure during a hospital visit. (Getty Images)
CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER
She continued, “When I was in bed for those two days, and it was sort of the end of it, and I was just wanting to come off it – because it’s not like you can stop taking it, it’s not like a pill or something that you don’t take when you wake up in the morning, it’s in your system, and it’s there.”
“I felt so sick one day I said to my friend, ‘I can’t keep any water down, I can’t keep any food down, no liquids, nothing. I need to go to hospital, I feel really sick.'”
Lottie claimed she finally made a visit to the emergency room where the 26-year-old model had a seizure due to dehydration.
Lottie Moss, right, is the younger sister of Kate Moss. (Getty Images)
A spokesperson for Ozempic manufacturer Novo Nordisk told Fox News Digital in a statement, “We understand and empathize with the health challenges this patient has faced. While we cannot comment on this particular incident, we care deeply about the safety and well-being of patients who take our medicines and strongly recommend that all patients maintain close contact with their health care professional for proper diagnosis, appropriate treatment, ongoing guidance and careful monitoring.”
It was also noted “that Ozempic® (semaglutide injection) is for patients with type 2 diabetes and is a prescription-only medicine, meaning that it must be prescribed by a health care professional and should be taken as prescribed under their strict supervision. Patients must make any decisions about treatment together with their healthcare professional so that their doctor can assess whether it is appropriate to prescribe the medicine or not, based on their assessment of the patient’s individual medical profile. Accessing prescription-only medicines without a valid prescription poses a direct danger to health.
“Above all, patient safety is our top priority at Novo Nordisk. We work closely with the U.S. Food and Drug Administration and all regulatory agencies around the world to continuously monitor the safety profile of our medicines,” the statement concluded.